Navigation Links
Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting

NEW HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. announced that it presented clinical data in a poster session at the 12th Congress of the European Hematology Association (EHA) Meeting in Vienna, Austria on its lead anticancer agent Cloretazine(R) (VNP40101M) as a single agent in a multi-center international Phase II clinical trial in a subset of elderly patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and unfavorable cytogenetics.

The Phase II trial was conducted from March 2004 to May 2006. The study treated 129 patients of 60 years of age or older with previously untreated AML or high-risk MDS. Previously data were presented on 104 patients (Giles et al, Journal of Clinical Oncology, January 1, 2007). Treatment consisted of Cloretazine(R) (VNP40101M) in a 600 mg/m2 dose administered in a 30-60 minute infusion on day 1 (second induction allowed) and provided the option for an additional 400 mg/m2 as consolidation for responders (complete remission (CR) or complete remission with incomplete platelet count (CRp). The primary endpoint was overall response (CR and CRp). Overall survival and relapse-free survival were also analyzed.

Data were presented at the EHA Meeting in a subset of 59 patients with unfavorable cytogenetics. Of these patients, 28 (47%) had secondary AML, 21 (36%) had de novo AML, and 10 (17%) had high-risk MDS. Overall, the response rate in patients with unfavorable cytogenetics was 25%. Response by diagnosis was: de novo AML (48%); MDS (30%) and secondary AML (7%). Twelve (20%) patients died within 30 days of receiving induction treatment. The majority of early death was in patients with secondary AML and was due to disease progression.

Dr. Norbert Vey, head of the Leukemia Program, Department of Hematology, at the Institut Paoli-Calmettes in Marseille, France, commented, "Patients with unfavorab
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

Post Your Comments:
(Date:11/25/2009)...Call/--Hologic,Inc.(HologicortheCompany)(Nasdaq: H...remiumdiagnostics,medicalimagingsystemsandsurgical...n,isusingtheannualmeetingoftheRadiologicalSocietyo...ber29throughDecember3,2009tohighlightournewSecurVi...stationsoftware. ,, TheHologicSecurViewworkstat...
(Date:11/25/2009)...dsResearchGroup,Inc.releasedWave1ofits LaunchTren...yndicatedmarketresearchprojecttrackingthelaunchofC...oughthefirstsixmonthsofavailability.Eachwaveofther...rmatologistsandqualitativeinformationfromasubsetof...ouse,typicalpatienttypes,productperceptions,promot...
(Date:11/25/2009)...e/--AMPACFineChemicalsLLC(AFC),asubsidiaryofAmeric...hatitreceivedtheEnvironmentalResponsibilityandSust...mmit,sponsoredbytheCaliforniaManufacturersandTechn...ssociation(IEA)andtheChemicalIndustryCouncilofCali...sawardavailablefromallthreeorganizationsandgainssu...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 1AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 2AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 3AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 4AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 5AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 6AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 7AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 8AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 9AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 10AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 11AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 12AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 13AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 14AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 15AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 16AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 17AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 18AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 1AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 2AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 3First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 1First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 2First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 3
...reported in,the journal Pharmacogenomics suggests ...ic Factor gene (CNTF) may affect response to,antip...Pharmaceuticals,Inc., included patients with acute... with Fiapta(TM) (iloperidone), a novel atypical,a... FDA, or placebo.,Patients were also studied for a...
...r Blood-Derived Stem Cells and Strong In...NEW YORK, Feb. 28 NeoStem, Inc. (Amex: NBS ),whi...ssing and long-term,storage of adult stem cells fo...ositive research conclusions and industry trends p...sociation and at the recent Third Annual,Stem Cell...
Other Medicine Technology:Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 3NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 2NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 3NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 4
(Date:11/25/2009)..., SILVERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--...nterforDrugEvaluationandResearch,titled"ADifficult...rsintheNov.26,2009issueofTheNewEnglandJournalofMed.../prnh/20090824/FDALOGO ) ,, Inthearticle,Woodco...topainmedicationforthosewhoneeditandmanagingtheris...
(Date:11/25/2009)..., SANFRANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQu...inter Spare the Air Alert forThursda...firelogsoranyothersolidfuel,bothindoorsandoutdoors...yairqualitytomorrow,"saidJackBroadbent,executiveof...torespectthehealthoftheirneighborsandfellowcommuni...
(Date:11/25/2009)...-term survivors of testicular cancer who were trea...ere side effects, including neurological side effe...not treated with chemotherapy, according to a new ... of the National Cancer Institute . , Marianne B...nd University Hospital, in Bergen, Norway, and col...
(Date:11/25/2009)...fortuitous discovery that grew out of a collaborat...tentially offer hope to the nearly 10 million Amer... , Also known as hardening of the arteries, ...irculatory problem in which narrowed arteries redu...dered a red flag for vascular disease, heart attac...
(Date:11/25/2009)...udy follow-up period was too short to draw definit...AY, Nov. 25 (HealthDay News) -- In diabetic patien...o be no difference in outcomes at one year whether...th stenting, British researchers report. , Bypa...betic patients with coronary artery disease. Howev...
Breaking Medicine News(10 mins):Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3
...norrhea, one of the most common sexually transmitt...scientists say they are running // out of options ...ibe a group of commonly used antibiotics including...ion (CDC) says that the sexual disorder-that affec...
...rmaphrodites, commonly known as eunuchs, can now c...ive birth to babies - thanks //to a special proced...l Sciences (AIIMS) here. After proper diagnos...ier research and referral institute said. "T...
...Child abuse casts a shadow the length of a lifetim...tter Truth Little Sana was home alone, happ...while her mom eked out a living in a neighborhood .... He locked the door and raped her repeatedly. ...
...th allergy season in full bloom, the American Acad...ffering a reminder of what you can do to cope with...throat specialist can help. // This spring, p...s, nasal congestion and drainage, and sometimes he...
...ti-smoking campaigns highlighting the risk of resp... at women, according to a new study published in t...rofessor Robert Adams of the Queen Elizabeth Hospi...found hospital admissions and mortality from asthm...
...ctors should not shy away from writing letters of ... according to an article in the latest Medical Jou...igious society, some doctors may be wary of pennin... 'Letters can be dangerous in the hands of law...
Other Medicine News:Health News:Scientists Concerned About Gonorrhea’s Drug Resistanc 2Health News:New Procedure Paves Way for Eunuchs to Choose a Gender and Conceive 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 3Health News:April Showers Bring May Flowers – And Plenty of Pollen, To 2
Frazier
Ferguson-Frazier suction tube # 4
Ferguson-Frazier suction tube # 0
UltraLite® Plus Headlight System
Medicine Products: